PGHH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.2
| Stock Code | PGHH | Market Cap | 32,898 Cr. | Current Price | 10,146 ₹ | High / Low | 14,543 ₹ |
| Stock P/E | 38.3 | Book Value | 287 ₹ | Dividend Yield | 1.67 % | ROCE | 104 % |
| ROE | 75.7 % | Face Value | 10.0 ₹ | DMA 50 | 10,467 ₹ | DMA 200 | 12,065 ₹ |
| Chg in FII Hold | -0.09 % | Chg in DII Hold | -0.07 % | PAT Qtr | 301 Cr. | PAT Prev Qtr | 210 Cr. |
| RSI | 49.6 | MACD | 7.14 | Volume | 3,365 | Avg Vol 1Wk | 5,755 |
| Low price | 8,979 ₹ | High price | 14,543 ₹ | PEG Ratio | -45.6 | Debt to equity | 0.00 |
| 52w Index | 21.0 % | Qtr Profit Var | 12.2 % | EPS | 265 ₹ | Industry PE | 44.1 |
📊 Procter & Gamble Hygiene and Health Care (PGHH) demonstrates exceptional efficiency metrics with ROE at 75.7% and ROCE at 104%, supported by a debt-free balance sheet. The P/E of 38.3 is slightly below the industry average (44.1), making valuations reasonable given strong profitability. Dividend yield of 1.67% provides steady income. However, the negative PEG ratio (-45.6) suggests growth alignment issues, and the 52-week index at 21% indicates underperformance relative to peers.
💡 Ideal Entry Price Zone: Between 10,467 ₹ (50 DMA) and 12,065 ₹ (200 DMA). Accumulating near these levels offers a margin of safety compared to the current price of 10,146 ₹.
📈 Exit Strategy / Holding Period: For existing holders, PGHH is suitable for a long-term horizon (5+ years) given its strong efficiency and brand leadership. Exit should be considered if earnings growth continues to stagnate or if dividend payouts weaken. Otherwise, continue holding for compounding returns and steady dividends.
✅ Positive
- Exceptional ROE (75.7%) and ROCE (104%).
- Debt-free balance sheet ensures financial resilience.
- Dividend yield of 1.67% provides consistent income.
- Quarterly PAT growth of 12.2% YoY.
⚠️ Limitation
- Negative PEG ratio (-45.6) indicates growth misalignment.
- 52-week index at 21% shows underperformance.
- Low trading volume compared to peers.
- Minor decline in FII (-0.09%) and DII (-0.07%) holdings.
📉 Company Negative News
- Weak stock performance relative to 52-week highs.
- Growth metrics not aligned with valuation multiples.
📈 Company Positive News
- Quarterly PAT improved (301 Cr vs 210 Cr).
- Strong efficiency metrics with high ROE and ROCE.
- Debt-free balance sheet supports long-term stability.
🏭 Industry
- Consumer healthcare and hygiene sector benefits from steady demand.
- Industry PE at 44.1 highlights sector growth, with PGHH trading slightly below average.
🔎 Conclusion
PGHH is a fundamentally strong company with exceptional efficiency and a debt-free balance sheet. While growth alignment issues exist, its brand leadership and consistent dividends make it a reliable candidate for long-term investment. Investors can accumulate near 10,467–12,065 ₹ and hold for 5+ years to benefit from compounding returns and steady income.